Спасительная внутрипузырная химиотерапия митомицином С после безуспешной БЦЖ-терапии

1. Alhausen A.F., Prout G.R., Daly J.J. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976; 116: 575.

2. Soloway M.S., Sofer M., Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002; 167(4): 1573–83.

3. Smith J.A., Jr, Labasky R.F., Cockett A.T. et al. Bladder cancer clinical guidelines panel summary report on the management of non-muscle invasive bladder cancer (stages Ta, T1, and Tis). American Urological Association. J Urol 1999; 162: 1697.

4. Oosterlinck W., Lobel B., Jaske G. et al. Guidelines on bladder cancer. Eur Urol 2002; 41: 105.

5. Shelley M.D., Wilt T.J., Court J. et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004; 93(4): 485–90.

6. Bohle A., Bock P.R. Intavesical bacilli Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004; 63(4): 682–6.

7. Mostofi F.K., Sobin L.H., Torloni H. Histological Typing of Urinary Bladder Tumors: International Classification of Tumors, 10. Geneva: World Health Organization, 1973.

8. Catalona W.J., Hudson M.A., Gillen D.P. et al. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 1987; 137: 220–4.

9. Baniel J., Grauss D., Engelstein D., Sella A. Intravesical bacillus Calmette-Guerin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 1998; 52: 785.

10. Bretton P.R., Herr H.W., Kimmel M. et al. The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin. J Urol 1990; 143: 710–3.

11. Coplen D.E., Marcus M.D., Myers J.A. et al. Long term follow up of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: Analysis of possible predictors of response free of tumor. J Urol 1990; 144: 652–7.

12. Soloway M.S. Intravesical therapy for bladder cancer. Urol Clin North Am 1988; 15: 661–9.

13. Kaasinen E., Rintala E., Pere A.K. et al. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma. J Urol 2000; 164(1): 47–52.

14. Kaasinen E., Wijkstrom H., Malmstrom P.U. et al. Nordic Urothelial Cancer Group. Alternating mitomycin C and BCG instillations in treatment of carcinoma in situ of the urinary bladder: a Nordic study. Eur Urol 2003; 43(6): 637–45.

15. Guinan P., Richardson C., Hanna M. et al. BCG in the management of superficial bladder cancer. In: Therapeutic Progress in Urologic Cancers, New York: Alan R Liss; 1989. p. 447–53.

16. Koontz W.W. Jr, Heney N.M., Soloway M.S. et al. Mitomycin for patients who have failed on thiotepa. Urology 1985; 26 (Suppl) : 30–1.

17. Nadler R.B., Catalona W.J., Hudson M.A., Ratliff T.L. Durability of the tumor free response for intravesical BCG therapy. J Urol 1994; 152: 367–73.

18. Heney N.M., Ahmed S., Flanagan M.J. et al. Superficial bladder cancer: Progression and recurrence. J Urol 1983; 130: 1083.

19. Herr H.W. Tumor progression and survival in patients with T1G3 bladder tumors: 15 year outcome. Br J Urol 1997; 80: 762.

20. Lundholm C., Norlen B.J., Ekman P. et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1996; 156(2 Pt 1): 372–6.

21. Bohle A., Jocham D., Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169(1): 90–5.

22. Rintala E., Jauhiainen K., Rajala P. et al. Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. J Urol 1995; 154(6): 2050–3.

23. Rintala E., Jauhianen K., Kaasinen E. et al. Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder group. J Urol 1996; 156: 56.

24. Malmstrom P.U., Wijkstrom H., Lundholm C. et al. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999; 161(4): 1124–7.

25. Witjes J.A., van der Meijden A.P., Sylvester L.C. et al. Long-term follow-up of an EORTC randomized prospective trail comparing intravesical bacillus Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 1998; 52(3): 403–10.